Jade Ribbon Campaign

Global Hepatitis B Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Hepatitis B, Infectious causes of cancer, Clinical medicine, Health, Hepatitis, World Hepatitis Day, Jade Ribbon Campaign

b'The "Global Hepatitis B Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Hepatitis B Epidemiology and Patient Flow Analysis - 2021, provides Hepatitis B epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Hepatitis B Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Hepatitis B Epidemiology and Patient Flow Analysis - 2021, provides Hepatitis B epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Hepatitis B patients, history of the disease at the population level (Hepatitis B prevalence, Hepatitis B incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Hepatitis B patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Hepatitis B market sizing, assessing market potential, and developing drug forecast models\nIdentify Hepatitis B patients segments through age groups, gender, and disease sub-types\nEvaluate Hepatitis B market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005183/en/\n'

Global Hepatitis C Markets, Epidemiology and Patient Flow Analysis Report 2020-2035: Sizing, Market Potential, and Drug Forecast Models - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Infectious diseases, Pharmaceutical, Health, Hepatitis, Medical specialties, Health, Hepatitis B, Infectious causes of cancer, World Hepatitis Day, Jade Ribbon Campaign

b'The "Global Hepatitis C Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Hepatitis C Epidemiology and Patient Flow Analysis - 2021, provides Hepatitis C epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Hepatitis C Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Hepatitis C Epidemiology and Patient Flow Analysis - 2021, provides Hepatitis C epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Hepatitis C patients, history of the disease at the population level (Hepatitis C prevalence, Hepatitis C incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Hepatitis C patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Hepatitis C market sizing, assessing market potential, and developing drug forecast models\nIdentify Hepatitis C patients segments through age groups, gender, and disease sub-types\nEvaluate Hepatitis C market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005181/en/\n'

Hepatitis Therapeutics Market: Public Concerns of Morbidity and Mortality and Burden on Healthcare Systems of Hepatitis steers Growth, Market projected to expand at 2.3% CAGR from 2018 - 2026, TMR

Retrieved on: 
Tuesday, March 16, 2021
Healthcare-associated infections, Infectious causes of cancer, Medical specialties, Health, Viral diseases, Hepatitis, Hepatitis B, Jade Ribbon Campaign, Viral hepatitis

The prevalence of hepatitis in such large numbers across the world calls for well-grounded line of treatment for treatment of the disease to give birth to the hepatitis therapeutics market .

Key Points: 
  • The prevalence of hepatitis in such large numbers across the world calls for well-grounded line of treatment for treatment of the disease to give birth to the hepatitis therapeutics market .
  • The hepatitis C disease type in the hepatitis therapeutics market is projected to account for leading share among other key types of the disease.
  • Powered by the U.S., North America is at the forefront among other key regions in the global hepatitis therapeutics market.
  • Asia Pacific is predicted to emerge as a key region in the hepatitis therapeutics market in the forthcoming years.

Hepatitis Therapeutics Market: Public Concerns of Morbidity and Mortality and Burden on Healthcare Systems of Hepatitis steers Growth, Market projected to expand at 2.3% CAGR from 2018 - 2026, TMR

Retrieved on: 
Tuesday, March 16, 2021
Healthcare-associated infections, Infectious causes of cancer, Medical specialties, Health, Viral diseases, Hepatitis, Hepatitis B, Jade Ribbon Campaign, Viral hepatitis

The prevalence of hepatitis in such large numbers across the world calls for well-grounded line of treatment for treatment of the disease to give birth to the hepatitis therapeutics market .

Key Points: 
  • The prevalence of hepatitis in such large numbers across the world calls for well-grounded line of treatment for treatment of the disease to give birth to the hepatitis therapeutics market .
  • The hepatitis C disease type in the hepatitis therapeutics market is projected to account for leading share among other key types of the disease.
  • Powered by the U.S., North America is at the forefront among other key regions in the global hepatitis therapeutics market.
  • Asia Pacific is predicted to emerge as a key region in the hepatitis therapeutics market in the forthcoming years.

Global Hepatitis B Virus (HBV) Market Report 2021-2030: 10 Year Demand Forecast & Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 22, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Clinical medicine, Virology, Infectious causes of cancer, Hepadnaviridae, Hepatitis B, Hepatitis B virus, Hepatitis, HBV, Hepatitis B in China, Jade Ribbon Campaign

The "Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)" report has been added to ResearchAndMarkets.com's offering.
  • The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030, increasing at a CAGR of 29.41%, for the period of 2021-2030.
  • With the increase in the prevalence of hepatitis B, the demand for treatment of the disease is becoming prominent.
  • The report provides a comprehensive analysis of the global Hepatitis B Virus (HBV) Market.

North America Liver Disease Treatment Market to Hit $8.31 Bn, by 2027, at 5.2% CAGR: AMR

Retrieved on: 
Tuesday, October 27, 2020
Medical specialties, Clinical medicine, Hepatology, Health, Healthcare-associated infections, Liver, Organs, Hepatitis, Antiviral drug, Infectious causes of cancer, Hepatitis C, Jade Ribbon Campaign

Additionally, the lack of healthcare professionals for liver disease treatment has further impacted the market.

Key Points: 
  • Additionally, the lack of healthcare professionals for liver disease treatment has further impacted the market.
  • Based on treatment type, the antiviral drugs segment dominated the market in 2019, accounting for more than half of the North America liver disease treatment market.
  • On the basis of disease type, the hepatitis segment held the largest share in 2019, accounting for more than four-fifths of the North America liver disease treatment market.
  • The market across U.S. held the lion's share in 2019, contributing to more than four-fifths of the North America liver disease treatment market.

Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection

Retrieved on: 
Thursday, August 27, 2020
Medical specialties, Infectious diseases, RTT, Clinical medicine, Infectious causes of cancer, Hepadnaviridae, Vaccine-preventable diseases, Hepatitis, HBV, Arbutus Biopharma, Jade Ribbon Campaign

As part of the collaboration, the companies may add cohorts in the future, to evaluate other patient populations and/or combinations.

Key Points: 
  • As part of the collaboration, the companies may add cohorts in the future, to evaluate other patient populations and/or combinations.
  • William Collier, President and Chief Executive Officer of Arbutus, stated, Arbutus is focused on discovering and developing a cure for chronic hepatitis B.
  • We maintain this can best be accomplishedthrough a combination of agents with different mechanisms of action that target distinct parts of the virus lifecycle.
  • Assembly Biosciences, Inc.is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome.

HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China

Retrieved on: 
Sunday, May 24, 2020
Medical specialties, Medicine, RTT, Clinical medicine, Infectious causes of cancer, Hepatology, Hepatitis, Cirrhosis, Hepatitis B in China, Jade Ribbon Campaign

Hepatitis B has been known as a complex disease to treat, due to the challenge in distinguishing patients with an active infection.

Key Points: 
  • Hepatitis B has been known as a complex disease to treat, due to the challenge in distinguishing patients with an active infection.
  • These patients require intervention as opposed to patients with an inactive infection who require only standard monitoring without treatment.
  • Image Credits: Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy , Scientific Reports [ 2 ].
  • Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition) [J].

HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China

Retrieved on: 
Sunday, May 24, 2020
Medical specialties, Medicine, RTT, Clinical medicine, Infectious causes of cancer, Hepatology, Hepatitis, Cirrhosis, Hepatitis B in China, Jade Ribbon Campaign

Hepatitis B has been known as a complex disease to treat, due to the challenge in distinguishing patients with an active infection.

Key Points: 
  • Hepatitis B has been known as a complex disease to treat, due to the challenge in distinguishing patients with an active infection.
  • These patients require intervention as opposed to patients with an inactive infection who require only standard monitoring without treatment.
  • Image Credits: Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy , Scientific Reports [ 2 ].
  • Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition) [J].

Dynavax Donates 10,000 Doses of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Vaccine to Emergency Healthcare Providers and Hospital Staff to Protect Against Hepatitis B Infections Amidst COVID-19 Pandemic

Retrieved on: 
Wednesday, April 8, 2020
Medical specialties, Medicine, RTT, Infectious diseases, Hepatitis B, Infectious causes of cancer, Vaccines, Vaccination, Hepatitis, Vaccine, Viral hepatitis, Jade Ribbon Campaign

This donation of HEPLISAV-B to help prevent hepatitis B is an effective protection measure we can implement immediately to help keep our front-line healthcare workforce safe.

Key Points: 
  • This donation of HEPLISAV-B to help prevent hepatitis B is an effective protection measure we can implement immediately to help keep our front-line healthcare workforce safe.
  • According to the World Health Organization, there are 257 million people worldwide living with chronic hepatitis B leading to more than 887,000 deaths annually.
  • Thousands are risking their lives by stepping up to join the surge healthcare workforce, many who may not have received a complete hepatitis B vaccine series.
  • HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.